Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris
Glenmark Pharmaceuticals has announced that its Swiss subsidiary, Glenmark Specialty S.A. has entered into an exclusive licensing agreement with Lotus International for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.
Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris, whereas Lotus will be responsible for commercialisation of Ryaltris (subject to receipt of regulatory approvals), in these markets. Glenmark will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus.
Ryaltris developed by Glenmark, is a novel fixed-dose combination nasal spray. It is a metered, fixeddose, aqueous suspension, prescription drug product nasal spray for the treatment of symptoms associated with allergic rhinitis (AR) in adults and pediatric patients 12 years of age and older. It is approved by the US FDA for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in adults and pediatric patients 12 years of age and older